MRI-guided immunotherapy development for multiple sclerosis in a primate

被引：14

作者：

't Hart, BA ^{[1
]}

Smith, P

Amor, S

Strijkers, GJ

Blezer, ELA

机构：

[1] Biomed Primate Res Ctr, Dept Immunobiol, Rijswijk, Netherlands

[2] Erasmus Univ, Med Ctr, Dept Immunol, Rotterdam, Netherlands

[3] Eindhoven Univ Technol, Dept Biomed Engn, Biomed NMR, NL-5600 MB Eindhoven, Netherlands

[4] Univ Utrecht, Med Ctr, Image Sci Inst, Utrecht, Netherlands

来源：

DRUG DISCOVERY TODAY | 2006年 / 11卷 / 1-2期

关键词：

D O I：

10.1016/S1359-6446(05)03673-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Multiple sclerosis is a serious neurological disease that affects 1 in 1000 young adults in Europe and the USA. The development of an effective therapy for this enigmatic disease is plagued by the failure of many treatments to reproduce in patients the promising effects observed in animal models. This review describes a new preclinical model in a non-human primate that might help to bridge the gap between currently used animal models and the patients.

引用

页码：58 / 66

页数：9

共 71 条

[1] Heterologous immunity provides a potent barrier to transplantation tolerance [J].

Adams, AB ;

Williams, MA ;

Jones, TR ;

Shirasugi, N ;

Durham, MM ;

Kaech, SM ;

Wherry, EJ ;

Onami, T ;

Lanier, JG ;

Kokko, KE ;

Pearson, TC ;

Ahmed, R ;

Larsen, CP .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (12) :1887-1895

[2] Biozzi mice: Of mice and human neurological diseases [J].

Amor, S ;

Smith, PA ;

't Hart, B ;

Baker, D .

JOURNAL OF NEUROIMMUNOLOGY, 2005, 165 (1-2) :1-10

[3] The common marmoset:: A new world primate species with limited Mhc class II variability [J].

Antunes, SG ;

de Groot, NG ;

Brok, H ;

Doxiadis, G ;

Menezes, AAL ;

Otting, N ;

Bontrop, RE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11745-11750

[4] SAFETY AND EFFICACY OF THERAPEUTIC MONOCLONAL-ANTIBODIES IN CLINICAL-THERAPY [J].

BACH, JF ;

FRACCHIA, GN ;

CHATENOUD, L .

IMMUNOLOGY TODAY, 1993, 14 (09) :421-425

[5] Assessing treatment effects on axonal loss - evidence from MRI monitored clinical trials [J].

Barkhof, F .

JOURNAL OF NEUROLOGY, 2004, 251 (Suppl 4) :6-12

[6] Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease [J].

Bjartmar, C ;

Wujek, JR ;

Trapp, BD .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) :165-171

[7] Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis [J].

Bö, L ;

Geurts, JJG ;

Ravid, R ;

Barkhof, F .

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2004, 30 (02) :106-117

[8] Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses [J].

Boon, L ;

Brok, HPM ;

Bauer, J ;

Ortiz-Buijsse, A ;

Schellekens, MM ;

Ramdien-Murli, S ;

Blezer, E ;

van Meurs, M ;

Ceuppens, J ;

de Boer, M ;

't Hart, BA ;

Laman, JD .

JOURNAL OF IMMUNOLOGY, 2001, 167 (05) :2942-2949

[9] Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: The encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule [J].

Brok, HPM ;

Uccelli, A ;

de Rosbo, NK ;

Bontrop, RE ;

Roccatagliata, L ;

de Groot, NG ;

Capello, E ;

Laman, JD ;

Nicolay, K ;

Mancardi, GL ;

Ben-Nun, A ;

't Hart, BA .

JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :1093-1101

[10] Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p4O monoclonal antibody [J].

Brok, HPM ;

van Meurs, M ;

Blezer, E ;

Schantz, A ;

Peritt, D ;

Treacy, G ;

Laman, JD ;

Bauer, J ;

't Hart, BA .

JOURNAL OF IMMUNOLOGY, 2002, 169 (11) :6554-6563

← 1 2 3 4 5 6 7 8 →